Metagenomi Therapeutics (MGX) EBITDA (2023 - 2026)
Metagenomi Therapeutics (MGX) reported EBITDA of -$23.4 million for Q1 2026, up 7.02% year-over-year from -$21.8 million in Q1 2025, and down 3.2% quarter-over-quarter from -$22.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) EBITDA (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of EBITDA data on file, last reported at -$23.4 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$23.4 million, up 7.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.6 million (down 12.33% YoY), and the FY2025 annual result was -$88.3 million, down 14.32% from the prior year.
- EBITDA retreated to -$23.4 million in Q1 2026 per MGX's latest filing, from -$22.6 million in the prior quarter.
- Over five years, EBITDA peaked at -$10.7 million in Q2 2024 and troughed at -$25.3 million in Q1 2024.
- A 4-year average of -$19.8 million and a median of -$20.2 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA gained 18.64% in 2024, then slumped 87.93% in 2025.
- A 4-year view of EBITDA shows it stood at -$19.0 million in 2023, then dropped by 27.83% to -$24.3 million in 2024, then increased by 6.94% to -$22.6 million in 2025, then retreated by 3.2% to -$23.4 million in 2026.
- Business Quant data shows MGX's EBITDA at -$23.4 million in Q1 2026, -$22.6 million in Q4 2025, and -$20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Metagenomi Therapeutics | 46.60 Mn | 46.60 Mn | - | -23.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.36 Mn |
| Dec 31, 2025 | -22.64 Mn |
| Sep 30, 2025 | -20.39 Mn |
| Jun 30, 2025 | -20.16 Mn |
| Mar 31, 2025 | -25.13 Mn |
| Dec 31, 2024 | -24.33 Mn |
| Sep 30, 2024 | -16.87 Mn |
| Jun 30, 2024 | -10.73 Mn |
| Mar 31, 2024 | -25.33 Mn |
| Dec 31, 2023 | -19.03 Mn |
| Sep 30, 2023 | -19.75 Mn |
| Jun 30, 2023 | -13.18 Mn |
| Mar 31, 2023 | -16.11 Mn |